Arcutis to Present at Upcoming Investor Conference

Rhea-AI Summary

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced its participation in the Guggenheim 3rd Annual Neuro/Immunology Conference on November 16, 2021, at 1:00 p.m. EST. This late-stage biopharmaceutical company focuses on innovations in immuno-dermatology to improve treatment for patients with immune-mediated dermatological diseases. The conference will be virtual, and webcasts can be accessed on the company's website. Arcutis aims to revolutionize care for conditions like plaque psoriasis and atopic dermatitis, with key data readouts expected by the end of 2022.

WESTLAKE VILLAGE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, today announced that Arcutis management will participate in an upcoming investor conference in November.

Details for the company’s participation are as follows:

• Guggenheim 3^rd Annual Neuro/Immunology Conference (Virtual)
  Fireside Chat Date: Tuesday, November 16, 2021
  Fireside Chat Time: 1:00 p.m. EST

Webcasts for this conference may be accessed at the “Events & Presentations” section of the Company’s website at https://investors.arcutis.com/events-and-presentations. The replay of the webcast will be available on the Arcutis website following the conference.

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions, with one NDA submission filed with the FDA and three Phase 3 clinical data readouts anticipated by the end of 2022. The company’s lead program, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn and Twitter.

Forward-Looking Statements
This press release contains "forward-looking" statements, including, among others, statements regarding the potential for roflumilast to revolutionize the standard of care in plaque psoriasis and other inflammatory dermatological conditions. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 16, 2021, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:

Media
Amanda Sheldon, Head of Corporate Communications
(805) 418-5006
asheldon@arcutis.com

Investors
Eric McIntyre, Head of Investor Relations
(805) 418-5006
emcintyre@arcutis.com

FAQ

What is the date of Arcutis' participation in the Guggenheim Conference?

Arcutis will participate in the Guggenheim 3rd Annual Neuro/Immunology Conference on November 16, 2021.

What time will Arcutis' fireside chat occur during the conference?

The fireside chat will take place at 1:00 p.m. EST.

Where can I access the webcast of Arcutis' conference participation?

The webcast can be accessed in the 'Events & Presentations' section of Arcutis' website.

What are Arcutis' main focuses in dermatology?

Arcutis focuses on developing treatments for immune-mediated dermatological diseases, including plaque psoriasis and atopic dermatitis.

What key updates can we expect from Arcutis by the end of 2022?

Arcutis anticipates three Phase 3 clinical data readouts by the end of 2022, along with one NDA submission filed with the FDA.